Soto-Rodríguez A. et al., 2025: Enhancing penile function: the impact of a regenerative multimodal protocol on erectile dysfunction.

The article presents a study evaluating the efficacy and safety of a regenerative multimodal treatment protocol for erectile dysfunction (ED) that combines low-intensity shockwave therapy (LiST) using the F-SW Ultra device (Storz Medical), delivering between 5,000 and 6,500 shockwaves at an energy flux density of 0.5 mJ/mm2 and a frequency of 6 Hz, umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy (both intrapenile and intravenous), and hyperbaric oxygen therapy (HBOT).
Conducted at a private clinic in Costa Rica, the retrospective observational study involved 22 male participants diagnosed with ED, with erectile function measured using the Sexual Health Inventory for Men (SHIM) questionnaire at baseline and three months post-treatment. The results indicated a statistically significant improvement in SHIM scores (mean increase of 3 points, p = 0.0017) with no major adverse events reported.
The authors suggest that this multimodal approach may be a viable option for patients with ED, although they call for larger randomized controlled trials to further validate the findings.
Strengths of the article:
1. Novel approach by combination of therapies: The study explores an innovative approach by combining multiple therapies that target different aspects of the pathophysiology of ED, which may enhance treatment efficacy.
2. Positive outcomes: The significant improvement in SHIM scores suggests that the protocol has potential benefits for erectile function, particularly for those who may not respond well to conventional treatments.
3. Safety Profile: The absence of major complications and adverse events during the study period adds to the treatment's appeal from a safety perspective.
4. Clear Methodology: The study outlines a clear and structured approach to treatment, detailing the protocols for each therapeutic component.
Limitations of the article
1. Retrospective Design: The retrospective nature of the study limits the ability to draw causal conclusions about the efficacy of the treatment protocol and raises concerns about biases in patient selection and data collection.
2. Lack of Control Group: Without a control group, it is difficult to attribute improvements solely to the treatment; placebo effects and spontaneous recovery cannot be ruled out.
3. Small Sample Size: The small number of participants (22) reduces the statistical power of the findings and limits the generalizability of the results.
4. Short Follow-Up: A follow-up period of only three months is insufficient to evaluate the long-term sustainability of the treatment effects.
Further Recommendations:
1. Randomized Controlled Trials: Future studies should employ a randomized controlled design with larger, more homogeneous participant groups to validate the findings and establish causality.
2. Longer Follow-Up: Research should include longer follow-up periods to assess the durability of treatment effects over time.
3. Objective Measures: Incorporating objective measures of erectile function, such as penile Doppler ultrasound, could provide valuable insights into the physiological changes associated with treatment.
4. Optimal Treatment Protocol: Further research is needed to determine the most effective dosing strategies and treatment frequency for each component of the multimodal protocol.
Conclusion
The study presents promising preliminary data supporting a multimodal approach to treating erectile dysfunction. While the results are encouraging, the limitations inherent in the study design necessitate further investigation to substantiate the claims and to refine treatment protocols for optimal patient outcomes.

Jens Rassweiler